INTERNATIONAL MULTICENTRIC STUDY OF TAMOXIFEN VS. ANASTROZOL IN WOMEN POST-MENOPAUSICAS WITH CARCINOMA DUCTAL IN SITU IBIS II (DCIS).

ASTRAZENECA - PERU,0 个研究点目标入组 0 人开始时间: 2003年8月6日最近更新: 2023年9月4日

适应症

试验速览

暂无简介。

•a) All women must be post-menopausal and have between 40 to
•70 years. The post-menopausal state is defined as 1 or more of
•the following criteria: Greater than 60 years, bilateral Ortectomy, less than 60 years with uterus and amenorrhea of at least 12 months, less than 60 years without uterus and with FSH> 20 Ul / L.
•b) CDIS locally resected within the last 6 months.
•c) Having baseline bone densitometry within the last 2 years will be required in all women. A column radiograph to rule out
•Frailty fractures will also be required.

•a) Pre-menopausal woman.
•b) Any previous cancer in the last 5 years (except non-melanoma skin cancer or in situ cancer of the cervix).
•c) Current treatment with anticoagulants.
•d) Deep vein thrombosis or previous puimonar embolism.
•e) Transient ischemic cerebral accident (TIA) or previous cerebrovascular accident.
•f) Current or previous administration of Tamoxifen or Raloxifene or other SERMs for more than 3 months or participation in IBIS-I.
•g) Intention to continue with the use of hormone replacement therapy
•based on estrogens.
•h) Women who have had a prophylactic mastectomy or are planning to perform this procedure.
•i) Any woman with post-menopausal bleeding not explained.

发起方

ASTRAZENECA - PERU,